Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.
Piccioni DE, Selfridge J, Mody RR, Chowdhury R, Li S, Lalezari S, Wawrzynski J, Quan J, Zurayk M, Chou AP, Sanchez DE, Liau LM, Ellingson BM, Pope WB, Nghiemphu PL, Green RM, Wang HJ, Yong WH, Elashoff R, Cloughesy TF, Lai A.
Piccioni DE, et al.
Neuro Oncol. 2014 Jun;16(6):815-22. doi: 10.1093/neuonc/nou028. Epub 2014 Mar 13.
Neuro Oncol. 2014.
PMID: 24627236
Free PMC article.